Prospective evaluation of blood Epstein-Barr virus DNA load and antibody profile in HIV-related non-Hodgkin lymphomas.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 05 2021
01 05 2021
Historique:
pubmed:
23
3
2021
medline:
28
4
2021
entrez:
22
3
2021
Statut:
ppublish
Résumé
The value of Epstein-Barr virus (EBV) biomarkers on the prognosis of HIV-related non-Hodgkin's lymphoma (NHL) has been poorly explored in the combined antiretroviral therapy (cART) era. We evaluated EBV DNA load and EBV antibodies in HIV-NHL patients enrolled in the French ANRS-CO16 Lymphovir Cohort between 2008 and 2015. Whole blood and plasma EBV DNA load and serological profiles were analyzed in 76 HIV-infected patients at diagnosis of NHL and 6 months after the initiation of chemotherapy. Prechemotherapy whole blood (WB) and plasma EBV DNA loads were positive for 80 and 45% of HIV-NHL patients, respectively. Pretreatment WB EBV DNA positivity was associated with a positive plasma HIV-1 RNA load (relative risk (RR), 4.42 [1.33; 14.72]) and plasma EBV DNA positivity with EBV in situ detection (RR 10.62 [2.38; 47.49]). Following chemotherapy, the proportions of patients with positive WB or plasma EBV DNA declined from 81 to 23% (P < 0.0001) and from 43 to 8% (P < 0.0001), respectively. Estimated 2-year progression-free survival did not differ according to prechemotherapy WB positivity (82% versus 67%, P = 0.15) or plasma EBV DNA positivity (76% versus 81%, P = 0.52). The plasma EBV DNA load correlates with in situ EBV detection. The WB EBV DNA load correlates with HIV load. WB and plasma EBV DNA loads at NHL diagnosis do not constitute prognostic markers for HIV-NHL patients in the modern cART era.
Identifiants
pubmed: 33749224
pii: 00002030-202105010-00002
doi: 10.1097/QAD.0000000000002839
doi:
Substances chimiques
DNA, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
861-868Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Simard EP, Engels EA. Cancer as a cause of death among people with AIDS in the United States . Clin Infect Dis 2010; 51:957–962.
Lanoy E, Spano J-P, Bonnet F, et al. The spectrum of malignancies in HIV-infected patients in 2006 in France: the ONCOVIH study . Int J Cancer 2011; 129:467–475.
Vandenhende M-A, Roussillon C, Henard S, et al. Cancer-related causes of death among HIV-infected patients in France in 2010: evolution since 2000 . PLoS One 2015; 10:e0129550doi: 10.1371/journal.pone.0129550.
doi: 10.1371/journal.pone.0129550
Arvey A, Ojesina AI, Pedamallu CS, et al. The tumor virus landscape of AIDS-related lymphomas . Blood 2015; 125:e14–e22.
Carbone A, Volpi CC, Gualeni AV, Gloghini A. Epstein – Barr virus associated lymphomas in people with HIV . Curr Opin HIV AIDS 2017; 12:39–46.
Dolcetti R, Gloghini A, Caruso A, Carbone A. A lymphomagenic role for HIV beyond immune suppression? . Blood 2016; 127:1403–1409.
Shannon-Lowe C, Rickinson AB, Bell AI. Epstein–Barr virus-associated lymphomas . Philos Trans R Soc Lond B Biol Sci 2017; 372:0160271.
Ma S-D, Hegde S, Young KH, et al. A new model of Epstein – Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas . J Virol 2011; 85:165–177.
Münz C. Latency and lytic replication in Epstein – Barr virus-associated oncogenesis . Nat Rev Microbiol 2019; 17:691–700.
Okamoto A, Yanada M, Inaguma Y, et al. The prognostic significance of EBV DNA load and EBER status in diagnostic specimens from diffuse large B-cell lymphoma patients . Hematol Oncol 2017; 35:87–93.
Tisi MC, Cupelli E, Santangelo R, et al. Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma . Leuk Lymphoma 2016; 57:628–634.
Montgomery ND, Randall C, Painschab M, et al. High pretreatment plasma Epstein–Barr virus (EBV) DNA level is a poor prognostic marker in HIV-associated, EBV-negative diffuse large B-cell lymphoma in Malawi . Cancer Med 2019; 9:552–561.
Ul-Haq I, Dalla Pria A, Suardi E, et al. Blood Epstein – Barr virus DNA does not predict outcome in advanced HIV-associated Hodgkin lymphoma . Med Oncol 2018; 35:53.
Muncunill J, Baptista M-J, Hernandez-Rodríguez Á, et al. Plasma Epstein – Barr virus load as an early biomarker and prognostic factor of human immunodeficiency virus-related lymphomas . Clin Infect Dis 2019; 68:834–843.
Lupo J, Germi R, Lancar R, et al. Epstein – Barr virus biomarkers have no prognostic value in HIV-related Hodgkin lymphoma in the modern combined antiretroviral therapy era . AIDS 2019; 33:993–1000.
Leruez-Ville M, Seng R, Morand P, et al. Blood Epstein – Barr virus DNA load and risk of progression to AIDS-related systemic B lymphoma . HIV Med 2012; 13:479–487.
Van Baarle D, Wolthers KC, Hovenkamp E, et al. Absolute level of Epstein – Barr virus DNA in human immunodeficiency virus type 1 infection is not predictive of AIDS-related non-Hodgkin lymphoma . J Infect Dis 2002; 186:405–409.
Lupo J, Germi R, Costagliola D, Morand P, Besson C. Utility of Epstein – Barr virus biomarkers in human immunodeficiency virus-related lymphomas in the modern combined antiretroviral therapy era . Clin Infect Dis 2019; 68:891–892.
Antiretroviral Therapy Cohort Collaboration. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies . Lancet HIV 2017; 4:e349–e356.
Besson C, Lancar R, Prevot S, et al. High risk features contrast with favorable outcomes in HIV-associated Hodgkin lymphoma in the modern cART era, ANRS CO16 LYMPHOVIR cohort . Clin Infect Dis 2015; 61:1469–1475.
Besson C, Lancar R, Prevot S, et al. Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era . AIDS 2017; 31:2493–2501.
Germi R, Lupo J, Semenova T, et al. Comparison of commercial extraction systems and PCR assays for quantification of Epstein – Barr virus DNA load in whole blood . J Clin Microbiol 2012; 50:1384–1389.
Lupo J, Germi R, Semenova T, Buisson M, Seigneurin JM, Morand P. Performance of two commercially available automated immunoassays for the determination of Epstein – Barr virus serological status . Clin Vaccine Immunol 2012; 19:929–934.
Buisson M, Fleurent B, Mak M, et al. Novel immunoblot assay using four recombinant antigens for diagnosis of Epstein – Barr virus primary infection and reactivation . J Clin Microbiol 1999; 37:2709–2714.
Kimura H, Ito Y, Suzuki R, Nishiyama Y. Measuring Epstein – Barr virus (EBV) load: the significance and application for each EBV-associated disease . Rev Med Virol 2008; 18:305–319.
Piriou ER, van Dort K, Nanlohy NM, Miedema F, van Oers MH, van Baarle D. Altered EBV viral load setpoint after HIV seroconversion is in accordance with lack of predictive value of EBV load for the occurrence of AIDS-related non-Hodgkin lymphoma . J Immunol Baltim Md 2004; 172:6931–6937.
Stevens SJC, Blank BSN, Smits PHM, Meenhorst PL, Middeldorp JM. High Epstein – Barr virus (EBV) DNA loads in HIV-infected patients: correlation with antiretroviral therapy and quantitative EBV serology . AIDS 2002; 16:993–1001.
Stevens SJC, Smits PHM, Verkuijlen SAWM, et al. Aberrant Epstein – Barr virus persistence in HIV carriers is characterized by anti-Epstein-Barr virus IgA and high cellular viral loads with restricted transcription . AIDS 2007; 21:2141–2149.
Okamoto A, Yanada M, Miura H, et al. Prognostic significance of Epstein – Barr virus DNA detection in pretreatment serum in diffuse large B-cell lymphoma . Cancer Sci 2015; 106:1576–1581.
Kanakry JA, Hegde AM, Durand CM, et al. The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases . Blood 2016; 127:2007–2017.
Kanakry JA, Li H, Gellert LL, et al. Plasma Epstein – Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial . Blood 2013; 121:3547–3553.
Park JH, Yoon DH, Kim S, et al. Pretreatment whole blood Epstein – Barr virus-DNA is a significant prognostic marker in patients with Hodgkin lymphoma . Ann Hematol 2016; 95:801–808.
Fan H, Kim SC, Chima CO, et al. Epstein – Barr viral load as a marker of lymphoma in AIDS patients . J Med Virol 2005; 75:59–69.
Amiel C, Legoff J, Lescure FX, et al. Epstein – Barr virus load in whole blood correlates with HIV surrogate markers and lymphoma: a French national cross-sectional study . J Acquir Immune Defic Syndr 2009; 50:427–429.
Barta SK, Xue X, Wang D, et al. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients . Blood 2013; 122:3251–3262.
Barta SK, Samuel MS, Xue X, et al. Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma . Ann Oncol 2015; 26:958–966.
Chadburn A, Chiu A, Lee JY, et al. Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034 . J Clin Oncol 2009; 27:5039–5048.
Ok CY, Li L, Xu-Monette ZY, et al. Prevalence and clinical implications of Epstein – Barr virus infection in de novo diffuse large B-cell lymphoma in Western countries . Clin Cancer Res 2014; 20:2338–2349.
Levin LI, Chang ET, Ambinder RF, et al. Atypical prediagnosis Epstein – Barr virus serology restricted to EBV-positive Hodgkin lymphoma . Blood 2012; 120:3750–3755.
Halec G, Waterboer T, Brenner N, et al. Serological assessment of 18 pathogens and risk of AIDS-associated non-Hodgkin lymphoma . J Acquir Immune Defic Syndr 2019; 80:e53–e63.
Bertrand KA, Birmann BM, Chang ET, et al. A prospective study of Epstein – Barr virus antibodies and risk of non-Hodgkin lymphoma . Blood 2010; 116:3547–3553.
Bassig BA, Willhauck-Fleckenstein M, Shu X-O, et al. Serologic markers of viral infection and risk of non-Hodgkin lymphoma: a pooled study of three prospective cohorts in China and Singapore . Int J Cancer 2018; 143:570–579.
Teras LR, Rollison DE, Pawlita M, et al. Epstein – Barr virus and risk of non-Hodgkin lymphoma in the cancer prevention study-II and a meta-analysis of serologic studies . Int J Cancer 2015; 136:108–116.